Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
01 10월 2024 - 7:45PM
Business Wire
Addition of CN201, a next generation
CD3xCD19 bispecific antibody with potential applications in B-cell
malignancies and autoimmune diseases, broadens and fortifies
Merck’s pipeline
Merck (NYSE: MRK), known as MSD outside of the United States and
Canada, today announced the completion of the acquisition of CN201
from Curon Biopharmaceutical (Curon), a novel investigational
clinical-stage bispecific antibody for the treatment of B-cell
associated diseases.
“By actively depleting B-cells, CN201 offers applications
spanning both B-cell malignancies and autoimmune diseases. We look
forward to building upon the foundational work started by the Curon
team,” said Dr. Dean Y. Li, president, Merck Research
Laboratories.
CN201 is currently being investigated in Phase 1 and Phase 1b/2
clinical trials for the treatment of patients with relapsed or
refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory
B-cell acute lymphocytic leukemia (ALL), respectively. Preliminary
data suggest CN201 has activity in patients with relapsed or
refractory B-cell hematologic malignancies and is well tolerated,
potentially leading to significant and sustained reductions in
B-cell populations.
Transaction details
Under the agreement, Merck, through a subsidiary, has acquired
full global rights to CN201. As previously disclosed, the
transaction is being accounted for as an asset acquisition. Merck
is recording a pre-tax charge of approximately $750 million
(reflecting the upfront payment and other related costs), or
approximately $0.28 per share, which will be included in
third-quarter non-GAAP results and was not included in Merck’s
full-year financial outlook issued on July 30. As a matter of
policy, Merck provides updates to its financial outlook once each
quarter and will provide an update to its full-year financial
outlook when it reports third-quarter 2024 results on October
31.
About CN201
CN201 is a novel CD3xCD19-targeting T-cell-engager bispecific
antibody, designed to target B cells for elimination by T cells.
CN201 is currently being evaluated in Phase 1 and Phase 1b/2
clinical trials for the treatment of relapsed or refractory
non-Hodgkin’s lymphoma and relapsed or refractory acute lymphocytic
leukemia, respectively.
About Merck
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than
130 years, we have brought hope to humanity through the development
of important medicines and vaccines. We aspire to be the premier
research-intensive biopharmaceutical company in the world - and
today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive
global workforce and operate responsibly every day to enable a
safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect
with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline candidates that
the candidates will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001828681/en/
Media Contacts: Robert Josephson (203) 914-2372 Carly Myar (917)
227-5957 Investor Contacts: Peter Dannenbaum (732) 594-1579 Damini
Chokshi (732) 594-1577
Merck (NYSE:MRK)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Merck (NYSE:MRK)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024